Starts in 1 month from now
LocationBrussels
There is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
On 5 and 6 March 2025, the German Federal Ministry of Education and Research (BMBF) is organising a symposium on the European Security Research Programme.
Here are some of the topics covered during this 2-day event:
The full agenda of the symposium can be found here.
Registration is required and can be done via this link.
Additionally, participants of this event are invited to a Pre-Symposium Workshop on 4 March 2025 titled ‘Future Scenarios and the Urgent Need for Research and Innovation,’ taking place from 13:00 to 16:30. This workshop is organised by the Dutch Ministry of Justice and Security.
During the workshop, the ministry will share insights from its future foresight work, offer a real scenario planning experience, and provide an open space to discuss the urgent need for research and innovation.
The workshop is open to symposium participants (max. 50 attendees). More information about the Pre-Symposium Workshop can be found here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Digital, Industry & Space Climate, Energy, Mobility AI, data & cloud Deployment: Best use of technologies
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.